Atyr Pharma Inc. (NASDAQ:LIFE) shot up 6.8% during trading on Wednesday . The stock traded as high as $3.31 and last traded at $3.30, with a volume of 158,901 shares changing hands. The stock had previously closed at $3.09.

Several brokerages have commented on LIFE. BMO Capital Markets reaffirmed a “hold” rating on shares of Atyr Pharma in a research note on Thursday, May 12th. Zacks Investment Research downgraded shares of Atyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $23.75.

The stock has a 50 day moving average of $2.85 and a 200 day moving average of $3.88. The company’s market capitalization is $77.93 million.

Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.02. On average, analysts expect that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In other Atyr Pharma news, insider Grove Matsuoka bought 12,412 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $37,732.48. Following the transaction, the insider now directly owns 2,412 shares in the company, valued at $7,332.48. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC raised its stake in Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned 5.10% of Atyr Pharma worth $11,857,000 at the end of the most recent quarter.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.